JP2017061453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017061453A5 JP2017061453A5 JP2016190522A JP2016190522A JP2017061453A5 JP 2017061453 A5 JP2017061453 A5 JP 2017061453A5 JP 2016190522 A JP2016190522 A JP 2016190522A JP 2016190522 A JP2016190522 A JP 2016190522A JP 2017061453 A5 JP2017061453 A5 JP 2017061453A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administration
- composition according
- relaxin
- heart failure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 108090000103 Relaxin Proteins 0.000 claims 4
- 102000003743 Relaxin Human genes 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 3
- 239000002934 diuretic Substances 0.000 claims 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010016807 Fluid retention Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 101800001904 NT-proBNP Proteins 0.000 claims 1
- 102400001263 NT-proBNP Human genes 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000000702 anti-platelet effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 230000001447 compensatory effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 230000036581 peripheral resistance Effects 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000036593 pulmonary vascular resistance Effects 0.000 claims 1
- 230000008327 renal blood flow Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12788908P | 2008-05-16 | 2008-05-16 | |
| US61/127,889 | 2008-05-16 | ||
| US19054508P | 2008-08-28 | 2008-08-28 | |
| US61/190,545 | 2008-08-28 | ||
| US20124008P | 2008-12-08 | 2008-12-08 | |
| US61/201,240 | 2008-12-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014129744A Division JP2014237648A (ja) | 2008-05-16 | 2014-06-25 | 慢性心不全の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017061453A JP2017061453A (ja) | 2017-03-30 |
| JP2017061453A5 true JP2017061453A5 (enExample) | 2017-07-13 |
Family
ID=41319370
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509781A Withdrawn JP2011520917A (ja) | 2008-05-16 | 2009-05-15 | 慢性心不全の治療方法 |
| JP2014129744A Withdrawn JP2014237648A (ja) | 2008-05-16 | 2014-06-25 | 慢性心不全の治療方法 |
| JP2016190522A Pending JP2017061453A (ja) | 2008-05-16 | 2016-09-29 | 慢性心不全の治療方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509781A Withdrawn JP2011520917A (ja) | 2008-05-16 | 2009-05-15 | 慢性心不全の治療方法 |
| JP2014129744A Withdrawn JP2014237648A (ja) | 2008-05-16 | 2014-06-25 | 慢性心不全の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20110144019A1 (enExample) |
| EP (2) | EP3150219A1 (enExample) |
| JP (3) | JP2011520917A (enExample) |
| CN (2) | CN104815319A (enExample) |
| AU (1) | AU2009246112B2 (enExample) |
| BR (1) | BRPI0912559A2 (enExample) |
| CA (1) | CA2724535A1 (enExample) |
| MX (2) | MX2010012502A (enExample) |
| RU (1) | RU2512933C2 (enExample) |
| WO (1) | WO2009140657A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2724540C (en) | 2008-05-16 | 2014-07-08 | Corthera, Inc. | Treating dyspnea associated with acute heart failure with relaxin |
| BR112012022654A2 (pt) | 2010-03-10 | 2016-11-01 | Univ Florida | modulação de aquaporinas com relaxina |
| US20130336979A1 (en) * | 2010-12-01 | 2013-12-19 | Fatima Smih | Diagnostic and treatment of chronic heart failure |
| MX2014000316A (es) * | 2011-07-08 | 2014-02-19 | Bayer Ip Gmbh | Proteinas de fusion liberadoras de relaxina y usos de las mismas. |
| AU2012291972B2 (en) * | 2011-08-04 | 2017-03-09 | Pharis Biotec Gmbh | Process for preparing human relaxin-2 |
| WO2013033324A2 (en) | 2011-08-31 | 2013-03-07 | University Of Florida Research Foundation, Inc. | Materials and methods for modulating activity of bone marrow derived cells |
| US20140364334A1 (en) * | 2011-12-21 | 2014-12-11 | Nuclea Biotechnologies, Inc. | Congestive heart failure biomarkers |
| EP2814513B1 (en) | 2012-02-14 | 2017-12-20 | The Regents of The University of California | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
| WO2014115033A2 (en) * | 2013-01-25 | 2014-07-31 | Cardiorentis Ltd. | Methods of treating cardiovascular indications |
| HK1211594A1 (en) * | 2013-11-07 | 2016-05-27 | 上海恒瑞医药有限公司 | Human relaxin analogue, pharmaceutical composition of same, and pharmaceutical application of same |
| US10500227B2 (en) * | 2014-12-03 | 2019-12-10 | University Of Cincinnati | Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease |
| DK3387019T3 (da) | 2015-12-09 | 2022-01-10 | Scripps Research Inst | Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder |
| MX2019008449A (es) | 2017-02-08 | 2019-09-09 | Bristol Myers Squibb Co | Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos. |
| CN107335051A (zh) * | 2017-08-18 | 2017-11-10 | 温州医科大学附属第医院 | 一种保护慢性心衰肾功能的药物组合物 |
| US20220008508A1 (en) * | 2018-11-20 | 2022-01-13 | Universität Heidelberg | Relaxin receptor 1 for use in treatment and prevention of heart failure |
| US12226455B2 (en) | 2019-11-16 | 2025-02-18 | Relaxera Pharmazeutische Gmbh & Co. Kg | Medical composition for treating cardiac wasting and cachexia |
| EP4192580A4 (en) * | 2020-08-05 | 2025-06-18 | AskBio Inc. | Methods for treating heart disease and congestive heart failure and administration of AAV vectors |
| RU2748529C1 (ru) * | 2020-09-01 | 2021-05-26 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ определения этиологии хронической сердечной недостаточности |
| IL321288A (en) * | 2022-12-09 | 2025-08-01 | Astrazeneca Ab | Dosing regimens using fusions of relaxin heterodimers |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023321A (en) | 1982-12-13 | 1991-06-11 | Howard Florey Institute Of Experimental Physiology & Medicine | Molecular cloning and characterization of a further gene sequence coding for human relaxin |
| US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
| CA2165781C (en) | 1993-06-21 | 2007-02-13 | Tim Breece | Process for producing relaxin |
| US5811395A (en) | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
| RU2213559C2 (ru) * | 2000-01-26 | 2003-10-10 | Тюменская государственная медицинская академия | Способ лечения больных хронической сердечной недостаточностью на фоне ишемической болезни сердца |
| DE10155843A1 (de) * | 2000-11-16 | 2003-01-30 | Immundiagnostik Ag | Verfahren zur Prognose und Diagnose von Herzinsuffizienz |
| US20050113286A1 (en) * | 2002-03-18 | 2005-05-26 | Schreiner George F. | Methods for treating congestive heart failure |
| EP1729817B1 (en) * | 2004-03-30 | 2014-03-05 | Industry-Academic Cooperation Foundation | Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin |
| US20080077025A1 (en) * | 2005-07-11 | 2008-03-27 | Leticia Delgado-Herrera | Methods for determining how to treat congestive heart failure |
| WO2009007848A2 (en) | 2007-07-12 | 2009-01-15 | Compugen Ltd. | Bioactive peptides and method of using same |
| CA2724540C (en) * | 2008-05-16 | 2014-07-08 | Corthera, Inc. | Treating dyspnea associated with acute heart failure with relaxin |
-
2009
- 2009-05-15 CN CN201510202983.1A patent/CN104815319A/zh active Pending
- 2009-05-15 WO PCT/US2009/044247 patent/WO2009140657A2/en not_active Ceased
- 2009-05-15 EP EP16174665.6A patent/EP3150219A1/en not_active Withdrawn
- 2009-05-15 MX MX2010012502A patent/MX2010012502A/es active IP Right Grant
- 2009-05-15 AU AU2009246112A patent/AU2009246112B2/en not_active Ceased
- 2009-05-15 RU RU2010151470/14A patent/RU2512933C2/ru not_active IP Right Cessation
- 2009-05-15 CA CA2724535A patent/CA2724535A1/en not_active Abandoned
- 2009-05-15 JP JP2011509781A patent/JP2011520917A/ja not_active Withdrawn
- 2009-05-15 BR BRPI0912559A patent/BRPI0912559A2/pt not_active Application Discontinuation
- 2009-05-15 EP EP09747738A patent/EP2288366A4/en not_active Ceased
- 2009-05-15 CN CN2009801176516A patent/CN102026649A/zh active Pending
- 2009-05-15 MX MX2012010249A patent/MX336145B/es unknown
- 2009-05-15 US US12/992,667 patent/US20110144019A1/en not_active Abandoned
-
2013
- 2013-07-11 US US13/939,648 patent/US20140005112A1/en not_active Abandoned
-
2014
- 2014-06-25 JP JP2014129744A patent/JP2014237648A/ja not_active Withdrawn
-
2016
- 2016-04-25 US US15/137,054 patent/US20160287672A1/en not_active Abandoned
- 2016-09-29 JP JP2016190522A patent/JP2017061453A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017061453A5 (enExample) | ||
| Krell et al. | Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure | |
| den Uil et al. | Primary intra-aortic balloon support versus inotropes for decompensated heart failure and low output: a randomised trial | |
| Taguchi et al. | Effects of enhanced external counterpulsation on hemodynamics and its mechanism relation to neurohumoral factors | |
| JP2011520917A5 (enExample) | ||
| Szczepańska-Sadowska | Hemodynamic effects of moderate increase of the plasma vasopressin level in conscious dogs | |
| López-Rivera et al. | Treatment of hypertensive cardiogenic edema with intravenous high-dose nitroglycerin in a patient presenting with signs of respiratory failure: a case report and review of the literature | |
| Mills et al. | “BNP” for heart failure: role of nesiritide in cardiovascular therapeutics | |
| Simsic et al. | Perioperative effects and safety of nesiritide following cardiac surgery in children | |
| JP2016505065A5 (enExample) | ||
| Zineh et al. | The evolving role of nesiritide in advanced or decompensated heart failure | |
| Pensado et al. | Haemodynamic effects of propofol during coronary artery bypass surgery | |
| Sasaoka et al. | Low dose carperitide (alpha-hANP) administration is effective for preventing worsening renal function (WRF) and long-term renal protection | |
| Aundhakar et al. | Cardiorenal syndrome: Resistant to diuretics, sensitive to ultraflitration | |
| Piras | Hypovolemic shock | |
| Rajapreyar et al. | Novel pharmacotherapies for heart failure | |
| Evonuk | Hemodynamic and metabolic responses of infused low molecular weight dextran | |
| Silver et al. | Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of acutely decompensated heart failure | |
| Lee et al. | Forward blood flow provoked by changing intravascular pressure using an extracorporeal circulation during cardiopulmonary resuscitation. | |
| Kassar et al. | A Stab in the Heart: Scimitar Pulmonary Venous Anomaly Complicating a Case of Cardiogenic Shock | |
| Jennings et al. | Effect of 1 year's therapy in essential hypertension on systemic haemodynamics studied before and after ‘total’autonomic blockade | |
| Wittebole et al. | High-dose insulin therapy in a case of subarachnoid hemorrhage-related severe cardiodepression with ischemic-like electrocardiographic changes | |
| Solimando et al. | Emerging Concepts in Acute Heart Failure: From the Pathophysiology to the Clinical Case Based Approach | |
| Thompson et al. | Treatment of haemodynamic disturbance | |
| Ghaffari et al. | Pulmonary embolism in a patient with a rare coronary anomaly-a clue to the importance of proximal right coronary artery branches |